Brett Chevalier

Brett Chevalier is an experienced professional in the field of scientific research and operations. Brett currently holds positions at various companies including Anterra Capital, Orogen Therapeutics, BiomEdit, and Animol Discovery, Inc. Brett's expertise lies in iPSCs, cell state/fate/differentiation. Prior to their current roles, Brett also worked at CAMP4 Therapeutics, Corvium, Flagship Ventures, Whitehead Institute, and Agilent Technologies. Brett holds a PhD in Protein Design and Engineering from the University of Washington.